# Open-Label Absorption, Distribution, Metabolism, Excretion (ADME) and Pharmacokinetics (PK) Following a Single Oral Dose of AZD1236 in Healthy Male Subjects

> **NCT01007929** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 4 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 14C-AZD1236

## Key facts

- **NCT ID:** NCT01007929
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** —
- **Final completion:** 2009-11
- **Target enrollment:** 4 (ESTIMATED)
- **Why stopped:** Future development of AZD1236 is currently under review by the project team and no new studies will be started until this review is completed.
- **Last updated:** 2009-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01007929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01007929, "Open-Label Absorption, Distribution, Metabolism, Excretion (ADME) and Pharmacokinetics (PK) Following a Single Oral Dose of AZD1236 in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01007929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*